Beinaglutide

Beinaglutide is recombinant human GLP-1(7-36)amide with no acylation, PEGylation or fusion partner, so it is fully susceptible to DPP-4 and has a half-life measured in minutes. That makes it a pure prandial agent: injected before each main meal, it produces a short intense GLP-1 signal that slows gastric emptying and blunts the postprandial glucose rise, with satiety effects that translate into meaningful weight loss in Chinese populations at relatively low body weight. Its practical advantage is that being the native sequence it does not provoke anti-drug antibodies; its disadvantage is three injections a day.

Targets: GLP-1 receptor

• · Usually started at 100 mcg three times daily and increased to 200 mcg three times daily if tolerated. Skipping a meal means skipping that dose.

Work out your exact syringe units →

• very commonNausea— Short duration because the drug clears in minutes.
• very commonDecreased appetite— The intended effect.
• commonInjection-site reaction— Three injections a day adds up.
• uncommonHypoglycaemia with insulin or sulfonylureas

• History of pancreatitis.
• Pregnancy.
• Type 1 diabetes.
• Severe gastroparesis.

• redundantsemaglutide — Same receptor, far less convenient.
• cautioninsulin-analogues — Prandial timing overlaps directly with mealtime insulin.

• · Postprandial glucose.
• · Weight.
• · HbA1c.

Approved in China only; not approved in the US or EU.

• Chinese phase 3 registration trials of beinaglutide in type 2 diabetes and obesity (trial)

Beinaglutide is the control condition for the entire class - it is what GLP-1 receptor agonism looks like with no protraction engineering at all. That produces a specific and unusual clinical profile. Because plasma levels rise and fall within an hour, receptor occupancy is intermittent, and like lixisenatide the gastric-emptying arm never tachyphylaxes, so postprandial glucose control is good. Because there is no sustained central exposure, weight loss is modest - Chinese phase 3 data put it around 4-6 kg - and it accrues slowly. And because it must be given three times daily before meals, adherence is the binding constraint. The one genuinely interesting property is that as native GLP-1(7-36) amide it produces the full spectrum of endogenous GLP-1 signalling including the cleavage product GLP-1(9-36), which has its own poorly characterised cardiovascular and metabolic activity that engineered DPP-4-resistant analogues never generate. Whether that matters clinically is entirely unknown. Beinaglutide's evidence base is Chinese-population phase 3 trials with lower baseline BMI than Western obesity programmes, and it has never been evaluated by the FDA or EMA, so the percentages should not be assumed to transfer.

Three injections a day for 4-6 kg is a hard sell and adherence collapses. People also buy it expecting a semaglutide-like result because it is 'natural GLP-1', which inverts the actual pharmacology - the whole point of every modification in this class is that native GLP-1 does not last long enough to produce those results. And it is licensed only in China, so anything sold elsewhere has no regulatory oversight behind it.

• GLP-1 receptor (GLP1R) — Identical to native human GLP-1(7-36) amide by definition

  The full native response - glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay and satiety - for a matter of minutes per dose.

• Beinaglutide continuous subcutaneous infusion in newly diagnosed type 2 diabetes Randomised open-label · 2025

  Glycaemic efficacy and safety of continuous subcutaneous beinaglutide infusion in newly diagnosed type 2 diabetes.

Acts on the meal it precedes, within 15-30 minutes. No accumulation and no steady state in any meaningful sense. Weight effects accumulate over 8-12 weeks and plateau early.

The Chinese phase 3 registration data were largely in combination with metformin, which is the sensible pairing. Do not run it with any long-acting GLP-1 agonist - same receptor, and the short-acting agent adds nothing on top of continuous occupancy. Its only mechanistically distinctive niche would be postprandial control on top of a basal insulin, which is the same argument as for lixisenatide and has no beinaglutide-specific trial support.

Against semaglutide: not comparable. Twenty-one injections a week for a third of the effect. Against lixisenatide and exenatide immediate-release: the same short-acting prandial logic, executed with a human rather than lizard sequence, which means lower immunogenicity and even shorter duration. Its value is conceptual - it shows precisely how much of modern GLP-1 efficacy comes from pharmacokinetic engineering rather than from receptor pharmacology.

$80–$250/month. Chinese domestic pricing, converted approximately. Not available through Western pharmacies. Market observation, not verified pricing.

• ?No verifiable human pharmacokinetic parameters beyond the approximate half-life could be resolved - the Chinese regulatory package is not readily accessible in English.
• ?The claimed 4-6 kg weight loss comes from Chinese phase 3 trials that were not individually verified in this session.
• ?Whether the GLP-1(9-36) cleavage product contributes anything clinically is unknown.
• ?The sequence given is that of native human GLP-1(7-36) amide and is presented on that basis rather than from a verified product monograph.
• ?Cost figures are market observations, not verified pricing.

• Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial Luo Y et al., J Endocrinol Invest, 2025 · PMID 40719951

  One of the few beinaglutide trials indexed in English, and a direct illustration of the problem - the molecule works better by continuous infusion than by intermittent injection, because the half-life is 11 minutes.